# A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

> **NCT03747653** · — · UNKNOWN · sponsor: **Kaifeng Pharmaceutical (Group) Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** ADVATE
- **DRUG:** FRSW107

## Key facts

- **NCT ID:** NCT03747653
- **Lead sponsor:** Kaifeng Pharmaceutical (Group) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-08
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2020-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747653, "A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03747653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*